Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS-8112
- Development stage
- Discontinued
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Unknown (preclinical/experimental Stage)[5]
01
Overview
AS-8112 is a synthetic small molecule that acts as a selective antagonist at dopamine receptor subtypes D2 and D3 and the serotonin receptor 5-HT3. It has demonstrated potent antiemetic effects in animal studies by centrally inhibiting emesis induced by agents such as cisplatin and dopaminergic agonists. The drug was initially developed for potential use in treating nausea and vomiting but did not progress beyond preclinical development[1][2][3][5][7].
- Other names
- 5-bromo-N-[(6R)-1-ethyl-4-methyl-1,4-diazepan-6-yl]-2-methoxy-4-(methylamino)benzamideDB09207DB-09207DB 09207NS00073401NS-00073401NS 00073401
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on AS-8112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS-8112.